Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kris Jacobs

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Hemasphere|September 3, 2021
Oncogenic Cooperation Between IL7R-JAK-STAT Pathway MutationsInge Lodewijckx, Nicole Mentens, Kris Jacobs, et al.
Hemasphere|January 25, 2020
JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 InhibitorsInge Govaerts, Kris Jacobs, Roel Vandepoel, et al.
Haematologica|January 26, 2023
Combination therapy of a PSEN1-selective γ-secretase inhibitor with dexamethasone and an XPO1 inhibitor to target T-cell acute lymphoblastic leukemiaCharlien Vandersmissen, Cristina Prieto, Olga Gielen, et al.
Hemasphere|January 25, 2020
Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic LeukemiaDelphine Verbeke, Olga Gielen, Kris Jacobs, et al.
European Journal of Medicinal Chemistry|April 10, 2013
Identification of novel FLT3 kinase inhibitorsDaphnie Pauwels, Hugo Klaassen, Idoya Lahortiga, et al.
Journal of Hematology & Oncology|June 25, 2021
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemiaInge Govaerts, Cristina Prieto, Charlien Vandersmissen, et al.
Plos One|January 9, 2016
Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 SignalingSebastian K Wandinger, Idoya Lahortiga, Kris Jacobs, et al.
Leukemia|January 21, 2025
TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemiaLukas Lauwereins, Quentin Van Thillo, Sofie Demeyer, et al.
Blood|December 1, 2017
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALLSandrine Degryse, Simon Bornschein, Charles E de Bock, et al.
Blood|September 8, 2019
Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemiaMichael Broux, Cristina Prieto, Sofie Demeyer, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Hemasphere|September 3, 2021
Oncogenic Cooperation Between IL7R-JAK-STAT Pathway MutationsInge Lodewijckx, Nicole Mentens, Kris Jacobs, et al.
Hemasphere|January 25, 2020
JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 InhibitorsInge Govaerts, Kris Jacobs, Roel Vandepoel, et al.
Haematologica|January 26, 2023
Combination therapy of a PSEN1-selective γ-secretase inhibitor with dexamethasone and an XPO1 inhibitor to target T-cell acute lymphoblastic leukemiaCharlien Vandersmissen, Cristina Prieto, Olga Gielen, et al.
Hemasphere|January 25, 2020
Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic LeukemiaDelphine Verbeke, Olga Gielen, Kris Jacobs, et al.
European Journal of Medicinal Chemistry|April 10, 2013
Identification of novel FLT3 kinase inhibitorsDaphnie Pauwels, Hugo Klaassen, Idoya Lahortiga, et al.
Journal of Hematology & Oncology|June 25, 2021
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemiaInge Govaerts, Cristina Prieto, Charlien Vandersmissen, et al.
Plos One|January 9, 2016
Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 SignalingSebastian K Wandinger, Idoya Lahortiga, Kris Jacobs, et al.
Leukemia|January 21, 2025
TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemiaLukas Lauwereins, Quentin Van Thillo, Sofie Demeyer, et al.
Blood|December 1, 2017
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALLSandrine Degryse, Simon Bornschein, Charles E de Bock, et al.
Blood|September 8, 2019
Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemiaMichael Broux, Cristina Prieto, Sofie Demeyer, et al.
Pageof 2